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Background: SAVED and SOLVED trials showed Angiotensin converting enzyme inhibitors (ACEI) decrease cardiovascular (CV) mortality rate in low 
Ejection fraction (EF) patients, however PEACE and EUROPA trials didn’t show significant similar preventive effects in normal EF group. We evaluated 
baseline coronary artery calcium (CAC) score as a predictor of the ACEI use effect on outcomes among normal EF participants.
methodology: 4,208 who never used ACEI or were using ACEI (n=368, 8.7%) during all baseline and follow up examinations out of 6,814 the Multi 
Ethnic Study for Atherosclerosis (MESA) population were enrolled . Population (53.9% male) aged 60.8± 10.0 years (45-84) had no apparent clinical 
CV Disease. We compared CV event rates and multivariable-adjusted hazard ratios after stratifying by ACEI use and CAC (0, 1 to < 400 and >= 400).
results: The event rates varied from 1.8 to 41.2 per 1,000 person years among the groups (see table 1.) Among participants with 1 to <400 CAC 
score, ACEI users compare to non ACEI users showed significantly lower event rate (8.2 vs. 4.9, in order). Hazard ratio in adjusted model was 3.1 (CI= 
95%; 1.13, 8.78, P<0.05). There was no significant event rate difference between ACEI users and non users among other CAC groups.
conclusion: The use of ACEI was associated with significantly less CV events in patients with low to intermediate CAC scores and normal EF. CAC 
scores should be considered to evaluate the need for further CV risk reduction interventions in asymptomatic persons.
Table 1- Event Rate and Hazard Ratios (HR) of All CVD for Normal EF ACEi-CAC score groups; MESA
Event Rate Per
1,000 Person Years
HR (95% CI)
Unadjusted Model Adjusted Model 1 Adjusted Model 2
ACEi And CAC = 0
No ACEi And CAC = 0
4.2[4/129]
1.8[29/2147]
Reference
0.4(0.1, 1.2)
Reference
0.8(0.3, 2.4)
Reference
0.7(0.2,2.2)
ACEi And 0 < CAC < 400
No ACEi And 0 < CAC < 400
4.9[6/166]
8.2[85/1420]
Reference
1.7(0.7, 3.8)
Reference
2.8(1.1, 7.0)*
Reference
3.1(1.1, 8.5)*
ACEi And CAC >= 400
No ACEi And CAC >= 400
41.2[19/72]
17.9[35/274]
Reference
0.4(0.2, 0.7)**
Reference
0.6(0.3, 1.1)
Reference
0.5(0.3, 1.0)
